Hims & Hers vs. MyStart Health: prices, fine print, and the honest verdict

Tirzepatide pricing

Hims & Hers offers tirzepatide without a published price we could capture. MyStart Health carries only a reported figure — $179/mo from a competing comparison site (May 2026), never captured on a provider page — so it is listed, reviewed, and excluded from ranked comparisons pending verification.

Different products, not just different prices

Hims & Hers fulfills the FDA-approved product — reviewed manufacturing, verified identity and sterility, stable legal status — while MyStart Health sells compounded medication: pharmacy-prepared, not FDA-reviewed, and operating under the narrower post-shortage pathways our legal guide tracks. The compounded discount is partly a risk premium; whether it's worth taking depends on the pharmacy behind it and your tolerance for regulatory turbulence.

Transparency

Hims & Hers: No price published (verified 2026-08-05); names its pharmacy — brand fulfillment; compounded program closed to new patients. MyStart Health: Third-party-reported; dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

Hims & Hers: plan recurs; plan recurs until cancelled. MyStart Health: terms not published.

The five normalizations, applied to this pair

1 · All-in, not advertised. Hims & Hers bills at manufacturer/insurance rates plus any stated program fee; MyStart Health's reported $179 can't be normalized because no source page confirms what it includes. 4 · Evidence tiered. Hims & Hers: no price published, read 2026-08-05; MyStart Health: third-party-reported. 5 · Pharmacy weighed. Hims & Hers names brand fulfillment; compounded program closed to new patients; MyStart Health names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

Hims & Hers: no membership — the medication figure is the billed figure; plan recurs until cancelled. MyStart Health: no membership — the medication figure is the billed figure. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

Hims & Hers carries no price published pricing (last read 2026-08-05); pharmacy disclosure is its strong suit — brand fulfillment; compounded program closed to new patients, brand fulfillment. MyStart Health carries third-party-reported pricing; its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Neither program locks the door: a Hims & Hers-to-MyStart Health move is a new intake, a new prescription at the new pharmacy, and a written cancellation at the old shop — typically a one-to-two-week overlap if you time the last fill. What does not move with you: prepaid months, membership balances, and any dose paperwork, so re-state your current rung clearly at the new intake.

Refills, shipping, and the week-to-week reality

Past the pricing page, the operational facts are what a subscriber lives with: Hims & Hers: shipping included; consultation included in plan; async visit model. MyStart Health: shipping, consult, and refill logistics aren’t published in our capture — ask at intake, in writing. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick Hims & Hers if a named pharmacy is non-negotiable for you; only the FDA-approved product will do. Pick MyStart Health if its published terms happen to fit your state, format, or timing. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

What verification would take

For Hims & Hers, ranking would require: any published price at all, on a page we can capture and date; the dose structure (flat or scaled, with the 10 mg tier stated); the pharmacy's name, 503A/503B status, and state licensure; commitment and cancellation terms verbatim. For MyStart Health, ranking would require: a provider-page capture confirming the reported $179 figure and exactly what it includes; the dose structure (flat or scaled, with the 10 mg tier stated); the pharmacy's name, 503A/503B status, and state licensure; commitment and cancellation terms verbatim. We publish the checklist because the gap is fixable — providers that clear it get ranked on the same arithmetic as everyone else, and readers who ask these questions get the answers this page can't yet print.

If neither one fits

Two programs never exhaust the market — the nearest substitutes on the verified board are NexLife at $215 (flat, no membership, named pharmacy); Yucca Health at $258 (flat, no membership); IVIM Health at $278 (dose-scaled, $75 membership included) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The verdict

This one is a product decision more than a price decision — cheapest-possible compounded versus FDA-approved brand. Both records, with dates and sources, live in the pricing database.